A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)

NCT00529373 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

16071

Enrollment

INDUSTRY

Sponsor class

Conditions

Postmenopausal Osteoporosis

Interventions

DRUG: Odanacatib
DRUG: Placebo for Odanacatib
DIETARY_SUPPLEMENT: Vitamin D3
DIETARY_SUPPLEMENT: Calcium carbonate

Sponsor

Merck Sharp & Dohme LLC